Natalizumab Induction and Maintenance Therapy for Crohn's Disease - sprookjes - yvandenbroek - TriplyDB

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

http://www.wikidata.org/entity/Q22250890

about

Vedolizumab for induction and maintenance of remission in Crohn’s disease Anti-MAdCAM antibody for induction of remission in ulcerative colitis Vedolizumab for induction and maintenance of remission in ulcerative colitis Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis Natalizumab for induction of remission in Crohn's disease Natalizumab for induction of remission in Crohn's disease Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion Vedolizumab for the treatment of ulcerative colitis and Crohn's disease Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes Advances in the development of new biologics in inflammatory bowel disease The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Integrin-based therapeutics: biological basis, clinical use and new drugs Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Pharmacologic therapy for inflammatory bowel disease refractory to steroids Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease Anti-α4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis Next-Generation Therapeutics for IBD Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis Health-related quality of life during natalizumab maintenance therapy for Crohn's disease Severe and steroid-resistant Crohn's disease Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease Zinc and gastrointestinal disease The safety of vedolizumab for the treatment of ulcerative colitis.Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.TL1A: a mediator of gut inflammation Medical management of Crohn's disease: current therapy and recent advances.Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Biologics in inflammatory bowel disease: what are the data?

P2860

Q24187571-47F6B36C-00A3-43DB-A745-95C9A5A46235 Q24187593-A1775B88-83C0-4472-8CC0-3C64DA507645 Q24194423-A4A8DFFE-6E02-437C-984E-983E6FC351D3 Q24241123-9297F9C5-4D4A-4D84-AC65-F2362B892940 Q24245190-E63AE877-524E-4F5F-804F-A7B085CE06BB Q24246262-8C20106B-0679-4FFB-B1D4-0C4EA9496DFE Q24611768-B5D110CA-BA1C-4947-863B-2349FA4FA316 Q24630083-ED40B0BA-DD26-47EC-9F8E-D08B2DF465D9 Q24683776-5C2D4052-B87A-4D41-9473-6192CA5532B4 Q26745725-85E651C5-E360-4C17-AF3B-75DB5469542E Q26745782-65FCD70E-5DC1-401C-A53E-F085C0280B02 Q26748626-5B8BAA09-1309-44B6-B98E-78B86402A276 Q26750190-16212632-99CB-4DE0-986A-7B3C9A6CBD4E Q26750456-2267EA4C-FB64-44C2-A0E0-54D820BB976E Q26773026-DE63B1D3-1B67-4D6C-A005-4E8E01C75914 Q26773684-23552F24-0D12-40F0-9BCF-9A0BE305A289 Q26796415-E1016143-250C-4561-AF8C-4E78F5284A14 Q26822029-4FF26650-9474-437B-A3D9-F568453C5B5A Q26822941-261ECC6C-3983-4B86-B01C-661EC2382DB0 Q26864906-71711F45-B72C-43C0-92CA-4BB2D781FCE3 Q26999705-B283AC65-1A34-4173-8C3F-225DDD04F34B Q27005445-751150AF-E05F-40F6-9A1D-4D7B86F77BAA Q27322602-92BC45BF-1B31-426B-93AD-C3A4D4DF7A57 Q28067760-1B907F22-6AAF-4762-8F54-035E95DDA7EC Q28080984-0B71D593-8368-4331-A433-4213EF2D853D Q28082306-791A6E86-888C-45DE-9854-3353C57F1078 Q28083872-1C1467DB-EB6A-4793-A49B-8FD202CD64FB Q28084236-B5D5B692-5A53-4EFA-BBB8-EB0A0E2A5A19 Q28258882-B00AB136-CF6D-4636-842E-2B91F8C6EB83 Q28266806-5196A349-E838-476E-B3A5-08A17F745CB5 Q28538974-42BA11E4-213C-479E-952B-4871F95E5CCC Q28652224-6E18529A-DA3D-42F0-ADC4-467CAD1AE46A Q30235363-C3F518F7-0F12-4534-AA5A-62C59DE947FA Q30235581-F725A7F6-B917-48B0-90F1-799D369CC748 Q30300234-E881BD90-D022-4853-9A16-E9C219A3BEFA Q30445625-3D9742F0-DFB7-411B-B467-441B16D7E967 Q30450875-CA4C46D4-7A07-4CBC-8E46-1FDEEA2CE599 Q30815146-F0C33202-8614-40FA-B4F8-4490AECF84F0 Q30902172-D6A3445B-DB75-488E-A11F-EA49241EB57D Q31017419-9D9D2B2C-67EF-4E0C-AB73-FF8B40724A34

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

http://www.wikidata.org/entity/Q22250890

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@ast

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en-gb

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@nl

type

label

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@ast

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en-gb

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@nl

altLabel

Natalizumab induction and maintenance therapy for Crohn's disease

@en

prefLabel

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@ast

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en-gb

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@nl

P1433

Q22250890-428EBE5E-112B-4EC2-B650-B38DFC5FCA12

P1476

Q22250890-E562B483-80AB-4BCE-82A8-C6AE0DE09E2B

P2093

Q22250890-05100D1B-1CC0-489E-A2C7-77690B776BCF

Q22250890-0A74502A-AB44-496A-A8D4-8176B371595B

Q22250890-0C7C9096-1DB5-4D96-9193-383230FC98D5

Q22250890-26D8D4A5-6C58-4453-97EA-0DFEC09EA506

Q22250890-351B7465-359D-42AA-AF77-F139C326A03C

Q22250890-4E063DEE-44FC-475E-A801-6C36CC545990

Q22250890-6E139964-5505-443C-B755-310945847356

Q22250890-950A3F44-1923-4CDE-98E7-09D24019E995

Q22250890-A67A5575-8BAF-47F7-B9AC-07994F3F9200

Q22250890-F97FAEE0-13B5-4B3B-8CB4-F25C54F3C7CE

P304

Q22250890-86BDDB61-1796-4D61-B959-4B53FE2EC799

P31

Q22250890-9247195F-66DA-45CF-9D2F-87477375D889

P3181

Q22250890-B2F1AED0-B015-459F-855F-3F52BACF6A82

P356

Q22250890-D32E7F38-4758-4160-B576-5AF73F779174

P407

Q22250890-85FD31D7-0DB5-4BF0-946C-BF02A6D69A78

P433

Q22250890-3302CF53-6B19-44B5-8D85-89A80286CD8F

P478

Q22250890-838C7B4F-B27E-4A63-B9D7-49BA54CCBE6A

P50

Q22250890-021EBC25-9337-46AC-A660-5A9647797601

Q22250890-733C4A9B-055B-40AD-80F0-0B8D08D807A3

Q22250890-A757B95C-C2E4-4139-830B-C217463C9EE0

Q22250890-CB4FC0C3-2AC1-401F-8E6C-233D3B7E4119

Q22250890-E2F0E6FA-62E6-465B-ACB8-5855B09360A9

P577

Q22250890-649989FE-5383-46C9-9A97-6F05E359F765

P698

Q22250890-0FC09E3D-7F13-4B21-A9C7-B61FEA79B879

P921

Q22250890-20E562EE-4F34-4FFF-9AEE-6231210CAD64

P3181

P356

P1433

The New England Journal of Medicine

P1476

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

@en

P2093

Darrin Despain

http://www.w3.org/2001/XMLSchema#string

Gary S. Hogge

http://www.w3.org/2001/XMLSchema#string

Ian C. Lawrance

http://www.w3.org/2001/XMLSchema#string

Martin Sanders

http://www.w3.org/2001/XMLSchema#string

Remo Panaccione

http://www.w3.org/2001/XMLSchema#string

Roberts Enns

http://www.w3.org/2001/XMLSchema#string

Ronald Goldblum

http://www.w3.org/2001/XMLSchema#string

Sander van Deventer

http://www.w3.org/2001/XMLSchema#string

Stephan Targan

http://www.w3.org/2001/XMLSchema#string

Stephen B. Hanauer

http://www.w3.org/2001/XMLSchema#string

P304

1912-1925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3286650

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA043335

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

353

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Schreiber

Jean-Frédéric Colombel

William Jeffery Sandborn

Brian G. Feagan

P577

2005-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16267322

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease